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Abstract 
Background: Sentinel Lymph Node (SLN) sampling may significantly reduce surgical morbidity by avoiding need-
less radical lymphadenectomy. In gynaecological cancers, the current practice in the UK is testing the accuracy of SLN 
detection using radioactive isotopes within the context of clinical trials. However, radioactive tracers pose significant 
logistic problems. We, therefore, conducted a pilot, observational study to assess the feasibility of a novel optical 
imaging device for SLN detection in gynaecological cancers using near infrared (NIR) fluorescence.
Methods: A novel, custom-made, optical imaging system was developed to enable detection of multiple fluores-
cence dyes and allow simultaneous bright-field imaging during open surgery and laparoscopic procedures. We then 
evaluated the performance of the system in a prospective study of 49 women with early stage vulval, cervical and 
endometrial cancer who were scheduled to undergo complete lymphadenectomy. Clinically approved fluorescent 
contrast agents indocyanine green (ICG) and methylene blue (MB) were used. The main outcomes of the study 
included SLN mapping detection rates, false negative rates using the NIR fluorescence technique and safety of the 
procedures. We also examined the association between injection sites and differential lymphatic drainage in women 
with endometrial cancer by fluorescence imaging of ICG and MB.
Results: A total of 64 SLNs were detected during both open surgery and laparoscopy. Following dose optimisation 
and the learning phase, SLN detection rate approached 100 % for all cancer types with no false negatives detected. 
Fluorescence from ICG and MB detected para-aortic SLNs in women with endometrial cancer following uterine injec-
tion. Percutaneous SLN detection was also achieved in most women with vulval cancer. No adverse reactions associ-
ated with the use of either dyes were observed.
Conclusions: This study demonstrated the successful clinical application of a novel NIR fluorescence imaging system 
for SLN detection across different gynaecological cancers. We showcased the first in human imaging, during the same 
procedure, of two fluorescence dyes in women with endometrial cancer.
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Background
The most reliable currently used method for assessing 
lymph node (LN) status for staging purposes is to perform 
systematic lymphadenectomy. This is associated with a 
high degree of morbidity, particularly if adjuvant therapy 
is administered [1]. Complications include lymphoedema, 
lymphocyst formation, deep vein thrombosis, associated 
pressure symptoms and altered sensation in limbs. There 
is therefore a need for minimally invasive surgical proce-
dures to reduce post-operative morbidities that are asso-
ciated with systematic lymphadenectomy [2].
The role of sentinel lymph node (SLN) biopsy is an 
evolving concept in vulval, cervical and endometrial 
cancers [3]. Conventional methods for detecting SLNs 
include the use of vital dyes such as isosulphan-blue, pat-
ent-V and methylene blue, as well as radioisotope labelled 
agents [4, 5]. The concurrent use of two techniques pro-
duces exceptional detection rates in some cases [6]. How-
ever, exposure to ionising radiation and the need for a 
nuclear medicine unit limit the potential use of the radio-
active tracer technique.
Intra-operative near infrared (NIR) fluorescence has 
emerged as an alternative SLN imaging modality because 
of its high sensitivity and spatial resolution, as well as 
good depth penetration [7]. A number of studies in 
gynaecological cancers using indocyanine green (ICG) 
dye have shown detection rates comparable to the com-
bined vital-radiotracer method [8–10]. However, other 
studies reported lower detection rates [11–13]. This dis-
crepancy is likely due to a lack of practice standardisation 
when different imaging systems of given fluorescence 
sensitivity and varied injected doses are used. Moreover, 
the injection practice in endometrial cancers is still ques-
tionable, as cervical injection might not be appropriate 
for all endometrial tumours [14].
To address these issues, we conducted a clinical feasibil-
ity study across different cancer types using an in-house 
developed NIR fluorescence imaging system. The pri-
mary objective was to assess the feasibility of using this 
novel NIR fluorescence imaging system for SLN map-
ping in vulval, cervical and endometrial cancers during 
both open and laparoscopic surgery. Secondary objectives 
included determination of SLN fluorescence detection 
rates, injected dose optimisation, false negative rates and 
safety of the procedures. We also aimed to determine the 
association between injection sites and SLN detection in a 
subset of women with endometrial cancer by fluorescence 
imaging of two clinically approved fluorescent dyes.
Methods
Clinical trial
PIONIR (An observational PIlot Study Of Near Infra-
Red imaging of sentinel nodes in early stage vulval, 
cervical and endometrial cancers using indocyanine 
green and methylene blue as fluorophores to assess clini-
cal feasibility).
The study was approved by the independent Research 
Ethics Committee (REC) in Oxforsdshire and the Oxford 
University Hospital NHS Trust (Ethics Ref: 11/SC/0099) 
on 03 February 2012 and performed in accordance with 
the 1975 Helsinki Declaration ethical standards.
Study design and participants
This pilot study was performed at a tertiary cancer refer-
ral centre between October 2012 and September 2014. 
A total of 49 women with gynaecological malignancies 
were recruited. Participants had early vulval, cervical 
and endometrial cancers and were scheduled for com-
plete lymphadenectomy. Exclusion criteria included: (1) 
age <18 years; (2) pregnancy; (3) allergy to fluorescence 
dyes; (4) previous chemotherapy, radiotherapy or surgery 
to the LNs of interest; (5) patient vulnerability and (6) 
lack of capacity to provide informed consent or unwill-
ingness to inform the family doctor about participation 
in the study. Demographic and clinical data were col-
lected. Figure  1 shows a schematic decision tree flow-
chart of the procedure.
Fluorescence dyes and injection technique
Clinically approved, NIR fluorescence dyes, indocya-
nine green (ICG) and methylene blue (MB) were used 
according to the study protocol. ICG (25 mg vials, Pul-
sion Medical Systems, Munich, Germany) was re-sus-
pended in sterile water for injection to obtain an initial 
concentration of 5 mg/ml. The dye was freshly prepared 
on the day of surgery and one vial was used for each pro-
cedure. Following induction of general anaesthesia, 1 ml 
Fig. 1 Clinical study flowchart
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of ICG was injected immediately before surgery. Dye 
concentrations and volumes fluctuated during the ‘learn-
ing phase’ until an optimal detection rate was achieved. 
MB (Methylthioninium chloride, Provepharm SAS, 
Marseille, France) was supplied as ‘Proveblue’, being 
already dissolved in water to 5 mg/ml. The injected vol-
ume was 4 ml. Patients were continuously monitored for 
side-effects.
For vulval cancer patients, intradermal injection of ICG 
was performed using a 27G needle, with the needle held 
at a ~10° angle relative to the skin. Once the bevel pierced 
the epidermis, it was rotated by 180° before injection at 
each of four peri-scarring/tumoural margins. In women 
with cervical cancer, subepithelial ICG injection was 
performed using a 27G needle into the 3- and 9-o’clock 
positions, initially submucosally and then deep into 
the stroma, on both sides of the cervix. In women with 
endometrial cancer, cervical injection was performed, 
as described above. In two selected cases, a second dye 
injection into the uterine fundus (midline subserosa) 
was performed using a 23G epidural needle. In the first 
woman, cervical injection of ICG was followed by MB 
injection in the uterine subserosa. The second woman 
had reversed dye injection (i.e. MB in the cervix and ICG 
in the uterine subserosa).
Intra‑operative NIR fluorescence imaging
A custom-made laparoscopic attachment (Fig.  2a) and 
a wide-field imaging head (Fig.  2b) (described in [15]) 
were able to support both laparoscopic and open surgery 
procedures. Both systems share the same instrument 
control interface (Fig. 2c) and thus can be rapidly inter-
changed, if necessary. Two monochromatic (<4 nm band-
width) sources provided excitation light suitable for ICG 
and MB fluorescence imaging. A novel optical filtering 
arrangement allowed real-time simultaneous detection of 
bright-field colour images and fluorescence images from 
multiple dyes using a single camera. Fluorescence imag-
ing was performed after dye(s) injection using both wide-
field and laparoscopic imagers, as dictated by the surgical 
procedure. Live video images were displayed on the oper-
ating room monitors and the procedures were recorded. 
Exposure time during fluorescence acquisition ranged 
between 40 and 320  ms/frame, depending on the emis-
sion intensity and imaging depth. In a subset of vulval 
cancer patients, percutaneous NIR fluorescence imag-
ing was performed suprapubically prior to surgical pro-
cedure. The surgeon estimated whether the fluorescence 
signal was sufficient to warrant resection based on sub-
jective observation. Fluorescence from intra-operative 
hotspots was verified ex vivo using the same system.
Fig. 2 Fluorescence imaging system. a Laparoscopic camera attachment, b wide-field imaging head and c system control unit
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Surgical procedures
For cervical and endometrial cancer cases, laparoscopic 
and/or open surgery procedures were performed at the 
surgeon’s discretion. Pelvic side-walls were opened bilat-
erally along the external iliac vessels; internal iliac and 
obturator spaces were exposed prior to inspection with 
meticulous haemostasis to avoid obscuring lymphatic 
pathways. In women with vulval cancer, surgical dissec-
tion involved systematic exploration of both superficial 
and deep tissue planes over the femoral triangle and 
4-6 cm along the femoral vessels.
Specimen handling and histopathology
Once removed, the fluorescence hotspots and all the 
resected LNs during systematic lymphadenectomy were 
labelled and dispatched for histopathological examina-
tion. SLN identification was carried out using standard 
diagnostic criteria. All LNs were assessed for metas-
tases and their areas were measured. Histopathology 
was used to determine (1) the presence or absence of 
a SLN and (2) tumour metastasis in the excised speci-
mens. The pathological protocol involved ultra-staging 
of SLNs.
Statistical analysis
The mean age, number of hotspots identified and ana-
tomical location but not site were recorded. The hot-
spot detection rate was calculated as the ratio between 
the number of cases in which at least one hotspot was 
detected and the total number of cases. In line with pre-
vious studies, the SLN detection rate was calculated as 
the ratio between (a) the number of cases in which at 
least one hotspot was detected and confirmed to be a 
SLN by histological analysis, and (b) the total number of 
cases. Successive groups of ten cases were used to deter-
mine the learning curve.
The false negative rate was calculated as the num-
ber of cases in which at least one LN (non SLN) was 
positive and the SLN(s) was negative, divided by the 
total number of cases. The true positive rate was cal-
culated as the number of cases in which at least one 
fluorescently detected SLN was indeed correctly identi-
fied as a cancer positive LN divided by the total num-




Forty-nine women with a gynaecological cancer who 
underwent complete lymphadenectomy were included 
in this study: 11 (22.4  %) had vulval cancer, 10 (20.4  %) 
cervical cancer and 28 (57.2 %) endometrial cancer. Their 
mean age was 61.6 ± 13.2 (range 48–73) years.
Intra‑operative fluorescence detection
Intra-operative hotspot and SLN detection rates are rep-
resented by the learning curve shown in Fig. 3. Fluores-
cence hotspots differed slightly from SLN detection rates 
at the beginning of the study, indicating that some hot-
spots contained adipose tissue. Detection rates reached 
100  % after  ~30 cases, as shown in Table  1, along with 
total number of SLNs detected. The optimal injected 
concentration and volume were found to be 1  mg/ml 
and 4 ml respectively (optimised dose group in Table 1). 
Considering the optimised dose group only, the average 
number of SLNs per case was 2 (1–3) for vulval, 4 (4–4) 
for cervical and 1.5 (1–3) for endometrial cancers. The 
external iliac group of LNs was the commonest anatomi-
cal site for SLN detection for cervical and endometrial 
cancers. A series of snapshots from fluorescence imaging 
of lymphatic vessels and a left external iliac SLN in endo-
metrial cancer are shown in Fig. 4a. All intra-operatively 
identified hotspots were confirmed to be fluorescent by 
subsequent ex  vivo imaging. No residual hotspots were 
observed at the end of the procedures following system-
atic inspection of the surgical field. No adverse reactions 
associated with the use fluorescence dyes were observed.
Histopathological analysis
Metastasis in the excised LNs (including SLNs) was 
detected in 20.4 % of the cases. The detected SLNs cor-
rectly predicted the metastatic state of all the other LNs 
(no false negative SLNs) when the cases which corre-
sponded to the learning phase and dye optimisation were 
excluded. The false negatives and true positives rates are 
shown in Table 2.
Percutaneous SLN detection in vulval cancer
Percutaneous detection of inguinal SLNs, prior to sur-
gical incision, was attempted in seven women with vul-
val cancer using ICG fluorescence wide-field imaging. 
The fluorescence could be visualised as early as  ~6  min 
Fig. 3 SLN and fluorescence hotspot detection rate showing the 
learning curve associated with the study
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post-injection. Groin incision was then performed in 
the area corresponding to the percutaneous signal. The 
position of the SLN was accurately determined prior to 
resection. Percutaneous inguinal SLN detection was suc-
cessfully achieved in 5 out of 7 selected cases (71 %). A 
maximum imaging depth of ~20 mm was obtained using 
a camera exposure time of 80  ms (Fig.  4b; Additional 
file 1: Video S1).
Multi‑spectral fluorescence detection in endometrial 
cancer
Independent fluorescence imaging of ICG and MB was 
performed in two women with endometrial cancer. In both 
cases, fluorescence co-localisation of the dyes was observed, 
including sharing of common lymphatics (Fig. 4c), leading 
to an external iliac SLN irrespective of the injection site and 
dye (Additional file 2: Video S2). Notably, in the latter case a 
para-aortic SLN (true positive) was also detected with ICG 
only, following injection in the uterine fundus (Fig. 4d) but 
not by MB which was injected in the cervix.
Discussion
In gynaecological cancers, SLN detection appears to be 
an attractive and cost-effective alternative to complete 
lymphadenectomy without jeopardising correct LN stag-
ing (21). In an effort to modernise the surgical staging of 
regional LNs, we conducted a clinical feasibility study to 
address some of the disadvantages of the existing tech-
niques. We demonstrated the feasibility of using a novel, 
in-house developed fluorescence imaging system for SLN 
detection across all the major gynaecological cancers. 
Surrogate use of NIR fluorescence imaging may improve 
surgical nodal staging, exclude LN metastases and sub-
sequently reduce the risk of recurrence. Following the 
learning curve required for a new technique, we reported 
a cumulative SLN detection rate of 100  % and no false 
Table 1 Main study outcomes
All cases (n = 49) Optimised dose 
group (n = 16)
SLN detection rate Vulval 91 % 100 %
Cervical 90 % 100 %
Endometrial 68 % 100 %
Total 78 % 100 %
Average SLNs detected per woman Vulval 1.1 (0–4) 2 (1–3)
Cervical 2.3 (0–4) 4 (4–4)
Endometrial 0.9 (0–3) 1.5 (1–3)
Total 1.3 (0–4) 1.9 (1–4)
Fig. 4 Intra-operative fluorescence imaging. a Laparoscopic 
fluorescence imaging of ICG in a woman with endometrial cancer 
showing lymphatic vessels (yellow arrow heads, top) and a SLN (yellow 
arrow, bottom). b Percutaneous (top) and intra-operative (bottom) 
imaging of a ~20 mm deep SLN (yellow arrow) in vulval cancer using 
the wide-field imaging system. c Lymphatic co-localisation (yellow 
arrow heads) of MB (top) and ICG (bottom) following uterine and 
cervical injection, respectively, in a woman with endometrial cancer. 
d Para-aortic SLN (yellow arrow) fluorescence detection in a woman 
with endometrial cancer following uterine subserosa injection of ICG
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negatives. The total injected volume and concentration 
of dye(s) was optimised to be 4 ml and 1 mg/ml respec-
tively. No adverse reactions were observed following dye 
injection.
The main strength of this study was the achievement of 
the highest SLN detection rate using NIR fluorescence, 
which, in the context of a clinical trial, outperformed 
reported conventional methods based on blue dye and/
or radioactive tracer [6, 16, 17]. The learning curve indi-
cated a gradual increase in the detection rates following 
injection and dose optimisation and familiarity with the 
new technique. Our SLN detection rates agreed with pre-
vious studies performed using various NIR fluorescence 
imaging systems [8, 11, 21]. The detection rates were cal-
culated following exclusion of the initial 33 cases. The 
drop in detection rate after ~10 cases could be secondary 
to the later introduction of laparoscopic procedures. In 
fact, a larger number of laparoscopic cases were required 
to achieve a satisfactory detection rate, particularly for 
endometrial cancer. This relatively prolonged learning 
phase could be possibly justified by the disease heteroge-
neity (vulval, endometrial and cervical cancers) and the 
diversity of surgical procedures (open and keyhole sur-
geries) that were considered in this study, at the obvi-
ous advantage of SLN detection using the same imaging 
modality.
The use of a custom system that can operate as a wide-
field device as well as in conjunction with a laparoscope 
proved to be of significant benefit as fluorescence imag-
ing was performed irrespective of the surgical pro-
cedure. Moreover, the system allowed simultaneous 
bright-field and fluorescence visualisation whilst main-
taining reduced size and weight, making it suitable for 
hand-held operation. Adequate fluorescence sensitivity 
was reflected by the high intra-operative detection rates 
during laparoscopy and the percutaneous SLN detection 
rates in a large proportion of women (71 %) with vulval 
cancer, during open surgery.
Although most of the procedures (47/49) described in 
this study were performed following solely ICG injec-
tion, MB fluorescence dye was also used in two endo-
metrial cancer cases. Independent fluorescence imaging 
of two different fluorescence dyes (ICG and MB) was 
achieved by means of two separate imaging channels 
available in our instrument. This unique feature, which 
is not supported in widely used, commercially available 
NIR fluorescence systems, justified the development and 
usage of a novel imaging system. Unlike previous stud-
ies that used two different imaging modalities to detect 
SLN involvement from cervical and hysteroscopic injec-
tions [19], the use of two fluorescence dyes allowed for 
a more effective comparison and simultaneous examina-
tion of differential lymphatic drainage, as the same imag-
ing modality was adopted.
MB has been successfully used as a blue dye for SLN 
mapping in patients with endometrial cancer [20]. How-
ever, to the best of our knowledge, MB has never been 
used as a fluorescence dye to detect SLNs. We demon-
strated for the first time in a limited number of women 
(n = 2) that fluorescence SLN visualisation using MB is 
indeed feasible and provides considerably higher detec-
tion sensitivity in comparison to direct viewing. Never-
theless, further experience with fluorescence imaging of 
MB is required.
The fluorescently detected SLNs successfully pre-
dicted the metastatic status of the other LNs in all but 
four cases, all included in the learning phase. A possible 
explanation in these cases was the insufficient dose of dye 
or lack of experience. Pathological LN involvement on 
the ipsilateral side has also been suggested for SLN detec-
tion failure on one side [22]. The highest SLN detection 
rate was achieved with an ICG concentration of 1 mg/ml 
and injected volume of 4 ml. This finding was in agree-
ment with a recent meta-analysis on SLN fluorescence 
biopsy using ICG, which reported a superior detection 
rate in the sub-group of studies in which the injected vol-
ume was ≥2 ml and concentration <5 mg/ml [23].
We showcased extracorporeal visualisation of SLNs in 
the majority of women with vulval cancer following ICG 
injection which led to earlier SLN detection times. Such 
detection proved to be accurate up to a depth of ~20 mm 
below the skin. As SLNs in vulval cancer are superficially 
located, NIR fluorescence imaging has strong potential 
to reduce invasiveness as excision could be guided by 
transcutaneous fluorescence. However, difficulties were 
observed in patients with a high BMI (>30) as the avail-
able excitation light intensity could not penetrate the 
greater tissue thickness. This was in agreement with the 
findings from a similar study on vulval cancer [11].
We reported, for the first time in human, an independ-
ent fluorescence detection of ICG and MB in women 
with endometrial cancer, which revealed an association 
between injected site and SLN location. To date, there 
is still widespread controversy on the most appropri-
ate injection practice for SLN detection in endometrial 
cancer [14]. Given the limitations in the accessibility of 
peri-tumoural regions, a common practice is to inject 
the tracer in the cervical region [24]. Another important 
Table 2 Histopathological analysis results
All cases (n = 49) Optimised dose 
group (n = 16)
False negatives 4 (8 %) 0 (0 %)
True positives 6 (12 %) 2 (12.5 %)
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aspect of SLN detection is the ability to map the para-
aortic LNs, which also appears to be highly dependent 
to the injection location. Using fluorescence imaging at 
more than a single wavelength, we suggested that cervi-
cal injection in endometrial cancer might not be fully 
representative of the tumour. This was highlighted by 
the fluorescence detection of a para-aortic SLN, tak-
ing up only the dye (ICG) injected in the uterine fun-
dus. Although this finding was previously reported 
in studies in which women were either divided in 
two injection groups [25] or by using different imag-
ing modalities [19], our study is the first, in which both 
Table 3 Review summary of SLN biopsy in gynaecological cancers using NIR fluorescence
Reference Cancer type Surgical procedure Imaging device No. of patients Key results
Furukawa [26] Cervical Open Photodynamic eye  
(Hamamatsu)
12 At least 1 SLN identified in 
83 % of the patients
Crane [27] Cervical Open Custom made prototype 10 Intraoperative detection 
rate = 64 % relative to total 
number of ex vivo fluores-
cent SLNs
Crane [11] Vulvar Open Custom made prototype 10 Detection rates relative to 
gamma probe: fluores-
cence = 89.7 %, patent 
blue = 72.4 %
Van der Vorst [10] Cervical Open Mini-FLARE 9 At least 1 SLN identified 
in each patient. Optimal 
ICG:HSA dose: 500 μM
Rossi [28] Endometrial/cervical Robotic-assisted laparoscopy SPY scope (Novadaq) 20 At least 1 SNL identified in 
85 % of the cases
Holloway [8] Endometrial Robotic-assisted laparoscopy Da Vinci NIR fluorescence 
imaging system
35 At least 1 SLN identified in 
97 % of the patients with 
fluorescence and 77 % with 
calorimetric analysis
Hutteman [9] Vulvar Open Mini-FLARE 9 Detection rates relative to 
gamma probe: fluores-
cence = 100 %, patent 
blue = 71 %
Optimal ICG:HSA dose: 
750 μM
Schaafsma [29] Cervical Open Mini-FLARE 18 At least 1 SLN identified in 
97 % of the patients. No 
significant difference in 
signal-to-background ratio 
between ICG alone and 
ICG:HSA
Schaafsma [13] Vulval Open Mini-FLARE 24 Detection rates relative to 
gamma probe: fluores-
cence = 100 %, patent 
blue = 77 %
No significant difference in 
detection rate between ICG 
alone and ICG:HSA
Rossi [12] Endometrial Robotic-assisted laparoscopy SPY® scope (Novadaq) 29 SLN detection rate: 82 % for 
cervical injection, 33 % for 
hysteroscopic endometrial 
injection
Mathéron [18] Vulval Open Photodynamic eye  
(Hamamatsu)
15 SLN detection rate: 98 % 
radioactive, 96 % fluores-
cence, 65 % blue dye
Jewell [21] Endometrial/cervical Robotic-assisted laparoscopy PINPOINT® (Novadaq) 227 SLN detection rate: 95 %. 
Combined use of ICG and 
blue dye proved unneces-
sary
Sinno [30] Endometrial Robotic-assisted laparoscopy PINPOINT® (Novadaq) 71 Fluorescence ICG superior 
than blue dye (78.9 % vs. 
42.4 % bilateral detection 
rate)
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sites were concurrently injected in the same woman and 
the same imaging modality was employed to examine 
the aberrant lymphatic drainage independently. By this 
approach, we eliminated any in-between patient variabil-
ity and differences encountered in the detection sensitivi-
ties of radioactive and blue dye methods.
We carried out a comprehensive literature review for 
SLN detection using NIR fluorescence in gynaecologi-
cal caners (Table 3). The feasibility of SLN detection was 
demonstrated without any disparity in the safety profile. 
In all but one of the studies, the overall SLN detection 
rate ranged from 64 to 100 % using a variety of imaging 
devices. Our study, however, is the only one to report 
the use of the same imaging system, which can be used 
to standardise how SLN detection is compared across all 
cancer types. This is desirable when the imaging modality 
strongly relies on the sensitivity of the instrument.
Conclusion
This study demonstrated the feasibility of SLN mapping 
in women with vulval, cervical and endometrial can-
cers using a novel, customised NIR fluorescence imaging 
device. We showed a 100 % SLN detection rate and maxi-
mum specificity and sensitivity following learning phase 
and dose optimisation. We observed percutaneous SLN 
fluorescence in patients with vulval cancer during open 
surgery which resulted in reduced SLN detection times. 
We employed multiple fluorescence dyes to visualise inde-
pendent draining lymphatic paths in women with endo-
metrial cancer.
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